Pharmacological Profiles of Peptide Drug Candidates for the Treatment of Alzheimer's Disease-Reference-Cited by-同舟云学术

Pharmacological Profiles of Peptide Drug Candidates for the Treatment of Alzheimer's Disease

Published:2003-04 Issue:16 Volume:278 Page:13905-13911
ISSN:0021-9258
Container-title:Journal of Biological Chemistry
language:en
Short-container-title:Journal of Biological Chemistry

Author:

Adessi Céline,Frossard Marie-José,Boissard Christophe,Fraga Santiago,Bieler Sylvain,Ruckle Thomas,Vilbois Francis,Robinson Sandra M.,Mutter Manfred,Banks William A.,Soto Claudio

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference38 articles.

1. Toward a Comprehensive Theory for Alzheimer's Disease. Hypothesis: Alzheimer's Disease Is Caused by the Cerebral Accumulation and Cytotoxicity of Amyloid β-Protein

2. Alzheimer's disease and the amyloid cascade hypothesis: ten years on

3. Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease

4. β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy

5. Inhibition of Alzheimer's Amyloidosis by Peptides That Prevent β-Sheet Conformation

Cited by 175 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hydrophobic C-Terminal Peptide Analog Aβ_31–41 Protects the Neurons from Aβ-Induced Toxicity;ACS Chemical Neuroscience;2024-06-01

2. Sulfonamide Derivatives: Recent Compounds with Potent Anti-alzheimer’s Disease Activity;Central Nervous System Agents in Medicinal Chemistry;2024-04

3. Synthesis, biological evaluation and metadynamics simulations of novel N-methyl β-sheet breaker peptides as inhibitors of Alzheimer's β-amyloid fibrillogenesis;RSC Medicinal Chemistry;2024

4. Molecular Mechanisms of Inhibition of Protein Amyloid Fibril Formation: Evidence and Perspectives Based on Kinetic Models;International Journal of Molecular Sciences;2022-11-03

5. AmyP53, a Therapeutic Peptide Candidate for the Treatment of Alzheimer’s and Parkinson’s Disease: Safety, Stability, Pharmacokinetics Parameters and Nose-to Brain Delivery;International Journal of Molecular Sciences;2022-11-02